AZD5213 + pregabalin + Placebo + pregabalin capsules
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Trial Timeline
Nov 1, 2013 → May 1, 2015
NCT ID
NCT01928381About AZD5213 + pregabalin + Placebo + pregabalin capsules
AZD5213 + pregabalin + Placebo + pregabalin capsules is a phase 2 stage product being developed by AstraZeneca for Diabetic Neuropathy, Painful; Diabetic Neuropathies. The current trial status is completed. This product is registered under clinical trial identifier NCT01928381. Target conditions include Diabetic Neuropathy, Painful; Diabetic Neuropathies.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Neuropathy, Painful; Diabetic Neuropathies were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01928381 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful; Diabetic Neuropathies